Patents Issued in August 29, 2019
-
Publication number: 20190262248Abstract: A cosmetic composition and a method of preparing the cosmetic composition are provided. The method includes mixing at least one sulfate-free surfactant, at least one thickener, at least one hydrophilic emollient to form a mixture; and adding solvent to the mixture. The cosmetic composition is a clear, flowable semi-solid, and converts to a non-flowable semi-solid upon rubbing.Type: ApplicationFiled: February 28, 2018Publication date: August 29, 2019Inventors: Sara Robyn Muenz YOUSSEF, Kelly Marie GEORGE, Carol Ragai ELMASRY, Allison ELDER
-
Publication number: 20190262249Abstract: Described herein, a personal care composition and its uses, wherein the personal care composition comprises a surfactant system, wherein the surfactant system comprises: from 3% to 15% of an anionic surfactant by weight of the composition, wherein the anionic surfactant is sodium laureth(1) sulfate SLE1S, from 1% to 15% of one or more cosurfactants by weight of the composition; from 0.10% to 5.0%, from 0.20% to 2.5%, from 0.25% to 1.75%, from 0.50% to 1.Type: ApplicationFiled: February 27, 2019Publication date: August 29, 2019Inventors: Gerald John GUSKEY, Shannon Dale WAGERS, Edward Dewey SMITH, III
-
Publication number: 20190262250Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: ApplicationFiled: March 12, 2019Publication date: August 29, 2019Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Publication number: 20190262251Abstract: The present disclosure relates to compositions suitable as leave-in hairstyling compositions comprising (a) a first polysaccharide comprising inulin; (b) a second polysaccharide comprising carrageenan; (c) a third polysaccharide; and (d) a humectant. The compositions as leave-on hair styling do not require synthetic film-forming polymers nor do they require silicones. The leave-on hair styling compositions are particularly useful in methods for imparting durable styling or shaping benefits to hair.Type: ApplicationFiled: February 28, 2018Publication date: August 29, 2019Applicant: L'OREALInventors: Sana GHANI, Aziza Khader SULEIMAN, Vanessa DECARLO
-
Publication number: 20190262252Abstract: An oil based composition having a smooth sensation of use, which exhibits a superior unevenness correcting effect, and which may be filled in a container which is not airtight, is provided. An oil based composition includes, with respect to 100% by mass of the oil based composition: (a) 1 to 20% by mass of a dextrin fatty acid ester; (b) less than 5% by mass of a volatile oil component having a boiling point of less than or equal to 250° C. at normal pressure; (c) 10 to 60% by mass of a non volatile oil which is a liquid at normal temperature and normal pressure; and (d) 10 to 50% by mass of a silicone resin powder.Type: ApplicationFiled: November 17, 2016Publication date: August 29, 2019Inventors: Yuko NARUMI, Takahiro SUZUKI, Kiyoshi TAKAHASHI, Ken HIROSAKI, Tomoko IKEDA
-
Publication number: 20190262253Abstract: Disclosed is a topical skin composition. The composition can include 50 to 75% by weight of water, 2 to 7% by weight of caprylic/capric triglyceride, 2 to 7% by weight of Butyrospermum parkii (shea) butter, 2 to 7% by weight of Helianthus annuus (sunflower) seed oil, 1 to 5% by weight of cetyl alcohol, 1 to 5% by weight of glyceryl stearate, and 0.1 to 2% by weight of beeswax.Type: ApplicationFiled: May 8, 2019Publication date: August 29, 2019Inventors: Julia COLLIER, Michael FRUSHOUR, Kim WILSON
-
Publication number: 20190262254Abstract: Disclosed herein are oral care compositions comprising hemp seed oil and caprylyl glycol. In certain embodiments, the oral care composition optionally further comprises one or more ingredients selected from hyaluronic acid and aloe vera. Methods of making and using the compositions are also provided.Type: ApplicationFiled: May 8, 2019Publication date: August 29, 2019Applicant: Colgate-Palmolive CompanyInventors: Shamim ANSARI, Harsh Mahendra TRIVEDI, James MASTERS
-
Publication number: 20190262255Abstract: The present invention relates to non-toxic consumable compositions and formulations comprising chelator and base having synergistic effects on microbial metabolism and/or growth and/or pathogenic effectors and their use to promote and maintain health in mammals. The current invention also relates to non-toxic consumable compositions comprising more than one chelator and/or more than one base. The present invention further relates to methods for selecting said chelator and base composition and methods for detecting conditions in which selected compositions may be used. The present invention relates to the synergistic compositions and methods of their use for maintaining health, promoting health and treating diseases.Type: ApplicationFiled: September 27, 2018Publication date: August 29, 2019Inventor: Emily A. STEIN
-
Publication number: 20190262256Abstract: A cosmetic or pharmaceutical composition contains at least one polymer precursor and at least one polymerization catalyst in the presence of which the at least one polymer precursor polymerizes under the action of light. Also, a process for skin tautening, skin fixation and/or wrinkle reduction includes an elastic, wearable polymer layer being formed on the skin when a polymer precursor and a polymerization catalyst are topically applied on the skin area to be treated and the skin area to be treated is subsequently exposed to light.Type: ApplicationFiled: September 20, 2017Publication date: August 29, 2019Applicant: Mayser Pharma AGInventor: Klaus-Uwe BUSCH
-
Publication number: 20190262257Abstract: The present invention relates to matte lip compositions including at least one siloxysilicate resin, at least one polyorganosiloxane copolymer, and at least one lipophilic silica, and preferably including at least one non-lipophilic filler and at least one non-volatile hydrocarbon oil, as well as to methods of making and applying such compositions to lips.Type: ApplicationFiled: February 28, 2018Publication date: August 29, 2019Applicant: L'OREALInventors: Roselin ROSARIO-MELÉNDEZ, Susan Ashley DeSTENO, Chao ZHU
-
Publication number: 20190262258Abstract: A foaming oil cleanser composition and a method of preparing a foaming oil cleanser composition are provided. The foaming oil cleanser composition includes (a) a dialkyl sulfosuccinate, (b) Ricinus Communis Seed Oil, and (c) one or more oils. The foaming oil cleanser composition is essentially free of water and sulfate.Type: ApplicationFiled: February 27, 2018Publication date: August 29, 2019Applicant: L'OREALInventors: William Ronald FEUER, Miao WANG, Wivina LIJO
-
Publication number: 20190262259Abstract: Provided is a novel oral mucosa application material that has good handling properties, has excellent application properties for being applied to the oral mucosa even if moisture or saliva on the surface of the oral mucosa is heavy, and is provided with a property for improving the effect of physically protecting an application site by containing the moisture or saliva after application and showing elasticity, and further, a property for remaining at the application site for a long time. This oral mucosa application material is provided with a freeze-dried body containing a polymer on an adhesion surface to the oral mucosa. The content of the polymer in the freeze-dried body is 20 mass % or more, and the content of hyaluronic acid in the polymer is 50 mass % or more.Type: ApplicationFiled: July 25, 2017Publication date: August 29, 2019Applicant: RITAPHARMA, CO., LTD.Inventor: Kunio Yoneto
-
Publication number: 20190262260Abstract: The present invention includes a construct that comprises at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention also includes a pharmaceutical composition comprising a construct comprising at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention further includes a method of imaging a tissue or organ in a subject, a method of delivering a therapeutic cargo to a tissue or organ in a subject, and a method of treating a disease or disorder in a subject.Type: ApplicationFiled: March 4, 2019Publication date: August 29, 2019Applicant: DREXEL UNIVERSITYInventors: Steven P. WRENN, Stephen DICKER
-
Publication number: 20190262261Abstract: The present invention provides a novel radiosensitizer or anti-cancer chemotherapy sensitizer. In particular, the invention provides a radiosensitizer or anti-cancer chemotherapy sensitizer that can relieve the irritation of an affected area caused by hydrogen peroxide, is safe when injected into a human body, and can delay or reduce the degradation of hydrogen peroxide and thereby can efficiently exert a radiation sensitizing effect and an anti-cancer chemotherapy sensitizing effect. The radiosensitizer or anti-cancer chemotherapy sensitizer comprises a combination of (a) hydrogen peroxide and (b) hyaluronic acid or salt thereof.Type: ApplicationFiled: May 14, 2019Publication date: August 29, 2019Inventor: Yasuhiro Ogawa
-
Publication number: 20190262262Abstract: The present invention relates to a method of treating diabetes Type II by delivery of butyric acid, bile acid, long-chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a DPP-IV inhibitor such as vildagliptin.Type: ApplicationFiled: May 7, 2019Publication date: August 29, 2019Applicant: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20190262263Abstract: Drug products adapted for nasal delivery comprising naltrexone, alone or in combination with excipients, are provided. Pre-primed devices for intranasal administration of the drug products are also provided. In addition, methods for treating and preventing a variety of opioid receptor-mediated diseases, disorders, addictions, symptoms, reward-based behaviors, and conditions with the drugs products are provided.Type: ApplicationFiled: November 9, 2017Publication date: August 29, 2019Inventors: Roger Crystal, Edward T. Maggio
-
Publication number: 20190262264Abstract: The present invention relates generally to a methods of treating ear infections and clearing excess fluid from Eustachian tubes.Type: ApplicationFiled: May 13, 2019Publication date: August 29, 2019Inventor: Scott MOREHOUSE
-
Publication number: 20190262265Abstract: The invention provides gastric residence systems with configurations and geometrical dimensions that allow for improved shelf life during prolonged storage, and optimal residence properties when the systems are deployed in the stomach of a patient.Type: ApplicationFiled: December 7, 2016Publication date: August 29, 2019Inventors: Andrew BELLINGER, Rosemary KANASTY, Tyler GRANT, Colin GARDNER
-
Publication number: 20190262266Abstract: The invention provides liquid formulations comprising dissolved oxygen (e.g. 10 mg/L up to 100 mg/L dissolved oxygen), and a substance which is capable of forming a gel upon contact with a body surface or body tissues, wherein said gel is capable of releasing a therapeutically effective amount of dissolved oxygen. The substance capable of forming a gel may be thermogelling and may, for example, comprise a blend of poloxamers. The liquid formulations can be applied to body tissues whereupon they form a gel suitable for the treatment of a compromised tissue, for example a wound (acute or chronic), a burn, a skin disorder (e.g. psoriasis, acne, rosacea, or other dermatological condition such as atopic dermatitis), skin sores, or tissue necrosis. The liquid formulations are also suitable for use in the prevention or treatment of a bacterial biofilm on a body surface, e.g. on the skin. The invention further provides delivery devices (e.g.Type: ApplicationFiled: October 20, 2017Publication date: August 29, 2019Inventors: Ingrid MOEN, Hege UGLAND, Mahmood AMIRY-MOGHADDAM, Camilla HAGLERØD
-
Publication number: 20190262267Abstract: The present disclosure relates to a pharmaceutical solution having a toxicity-reducing effect for anti-tumor drugs, and a pharmaceutical composition comprising the solution as well as a method for using them. The pharmaceutical solution uses deuterium oxide as a solvent.Type: ApplicationFiled: May 9, 2019Publication date: August 29, 2019Inventor: Songyuan Chen
-
Publication number: 20190262268Abstract: The present invention relates to oral modified release compositions comprising plurality of modified release matrix particles and at least one pharmaceutically acceptable excipient; wherein the modified release matrix particles comprise at least one active agent, at least one release controlling agent and at least one pharmaceutically acceptable excipient. Further, the modified release composition is in the form of a suspension, dry formulation for reconstitution or dispersible tablet. The present invention also relates to a process for the preparation of these oral modified release pharmaceutical formulations.Type: ApplicationFiled: September 20, 2017Publication date: August 29, 2019Inventors: Pratibha Pilgaonkar, Anilkumar Gandhi, Paras Jain
-
Publication number: 20190262269Abstract: Provided is a polymeric micelle type DDS preparation that may efficiently exhibit pharmacological activity effects by enhancing migration characteristics, penetrability, and retention characteristics toward a diseased target tissue such as a tumor tissue or an inflammation-affected tissue, and thereby enhancing the action of a pharmacologically active substance. Disclosed is a block copolymer (A) having a hydrophilic polymer segment linked to a hydrophobic polymer segment, the hydrophilic polymer segment containing a polyethylene glycol chain, and the hydrophobic polymer segment containing a polyamino acid chain having a hydrophobic substituent in a side chain, wherein the hydrophilic polymer segment has a target binding site bonded thereto, and the main chain polymer combining the polyethylene glycol chain and the polyamino acid chain has a molecular weight of not less than 2 kilodaltons and not more than 10 kilodaltons.Type: ApplicationFiled: July 25, 2017Publication date: August 29, 2019Inventors: Dai Kurihara, Tsuyoshi Fukuda, Yuki Kawano, Keiichirou Yamamoto
-
Publication number: 20190262270Abstract: A solid preparation includes a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, which is stable to light even without light shielding coating. The solid preparation includes an active ingredient composed of a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, and one or more stabilizing agents selected from the group consisting of n-propyl gallate, sodium hydrogensulfite, dibutylhydroxytoluene, butylhydroxyanisole, tocopherol and D-isoascorbic acid, wherein the amount of the above active ingredient is 0.00001 to 0.01% by weight of the solid preparation, and the amount of the above stabilizing agent is 0.005 to 5% by weight of the solid preparation.Type: ApplicationFiled: July 28, 2017Publication date: August 29, 2019Applicant: Toray Industries, Inc.Inventors: Suguru TAKAKI, Satoshi MINAKAMI, Kotoe OHTA
-
Publication number: 20190262271Abstract: There is provided a nanocomplex having a core-shell structure. The shell of the nanocomplex comprises a functionalized hyaluronic acid while the core of the nanocomplex comprises a flavonoid encapsulating a metal-containing compound. Preferably, the flavonoid is epigallocatechin gallate (EGCG) and the hyaluronic acid is thiol-functionalized and subsequently conjugated to the flavonoid. There is also provided a method of forming the nanocomplex, a pharmaceutical composition comprising the nanocomplex, medical uses of the nanocomplex and a method of treating a patient, preferably with cancer using the nanocomplex.Type: ApplicationFiled: December 29, 2017Publication date: August 29, 2019Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Motoichi Kurisawa, Ki Hyun Bae, Susi Tan
-
Publication number: 20190262272Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.Type: ApplicationFiled: May 10, 2019Publication date: August 29, 2019Inventors: Arturo J. Vegas, Minglin Ma, Kaitlin M. Bratlie, Daniel G. Anderson, Robert S. Langer
-
Publication number: 20190262273Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.Type: ApplicationFiled: April 30, 2019Publication date: August 29, 2019Inventors: Ricardo Alberto VARGAS RINCON, Joseph REIZ
-
Publication number: 20190262274Abstract: Disclosed are crosslinked particles (e.g., microparticles) that are capable of storing and releasing drugs. The particles can be macroparticles, microparticles, or nanoparticles and can be composed of polyester backbones. The particles can be loaded with a drug. The particles can degrade in vivo to release the drug. The particles can be prepared by crosslinking functionalized polyester backbones and loaded with a given drug. The particles of the present disclosure can be injected with a syringe. In some embodiments, the particles of the present disclosure are administered in connection with a surgery and release the drug after the site of the surgery for a period of 1-6 months.Type: ApplicationFiled: February 27, 2019Publication date: August 29, 2019Inventors: Frantz Le Devedec, Christine Allen, David M. Stevens, Dean James Rager-Aguiar, Timothy Tordella Ruckh, Carl Eric Elmquist
-
Publication number: 20190262275Abstract: Materials and methods are described for forming self-assembled peptoid structures that are extremely stable, crystalline, free-standing and self-repairing are described. Based on the peptoid design, peptoid membranes in a 2D arrangement were able to roll into single-walled nanotubes with tunable sizes, diameters, thicknesses and stiffnesses as well as tailorable functions result. Crystalline nanomaterials made through this facile solution crystallization and anisotropic formation process are highly tailorable and exhibit a number of properties advantageous for applications such as water decontamination, cellular adhesion, imaging, surface coating, biosensing, energy conversion, biocatalysis or other applications.Type: ApplicationFiled: May 8, 2019Publication date: August 29, 2019Applicants: BATTELLE MEMORIAL INSTITUTE, WASHINGTON STATE UNIVERSITYInventors: Chunlong Chen, Mingming Wang, Teng-Yue Jian, Haibao Jin, Yuehe Lin, Yang Song, Dan Du
-
Publication number: 20190262276Abstract: A bioadhesive formulation, comprising gelatin, alginate and a coupling agent, capable of forming a bioadhesive matrix, which is characterized by rapid curing, optimal viscosity, high bonding strength, flexibility, biocompatibility and biodegradability, is disclosed. Further disclosed is such a bioadhesive formulation which further comprises a bioactive agent, and a drug-eluting bioadhesive matrix formed therefrom, the bioadhesive matrix being capable of delivering the bioactive agent to a bodily site. Methods utilizing the bioadhesive formulations and matrices in various biological and medical procedures are also disclosed.Type: ApplicationFiled: March 6, 2019Publication date: August 29, 2019Applicant: Active Healing Biomedical Ltd.Inventors: Meital Zilberman, Adaya Shefy-Peleg, Binyamin Cohen, Maytal Foox
-
Publication number: 20190262277Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.Type: ApplicationFiled: January 31, 2019Publication date: August 29, 2019Inventors: Walter Müller, Thomas Hille
-
Publication number: 20190262278Abstract: The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment (3) and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer (1) and an adhesive polymer layer (2) that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layers 1 and 2.Type: ApplicationFiled: May 8, 2019Publication date: August 29, 2019Inventors: Gerhard RITZDORF, Thomas HILLE, Petra BOTZEM, Gabriel WAUER, Marlene FUHRMANN
-
Publication number: 20190262279Abstract: The present application teaches a water-based skin emollient composition comprising water, a polyhydric alcohol, a diol, a thickener, and a pH-adjusting agent for use as a massage emollient during physical therapy applications, and methods of use therefor.Type: ApplicationFiled: July 1, 2016Publication date: August 29, 2019Inventors: Kevin Parker, Francis X. Osborne
-
Publication number: 20190262280Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome ASD are treated in the subject.Type: ApplicationFiled: May 14, 2019Publication date: August 29, 2019Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
-
Publication number: 20190262281Abstract: Provided is a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an active ingredient, and a method for preventing, alleviating or treating breast cancer using the composition by inhibiting the activity of polo-like kinase 1 (PLK1).Type: ApplicationFiled: October 19, 2017Publication date: August 29, 2019Applicant: KOREA UNITED PHARM. INC.Inventors: Keon Wook KANG, Kwang-Seok OH, Youngchul KIM, Sung Baek JEONG
-
Publication number: 20190262282Abstract: Disclosed herein are pharmaceutical compositions comprising at least one polycationic aliphatic amine, in particular spermidine, spermine or a combination thereof. The compositions can further comprise one or more selected from decarboxylated S-adenosylmethionine and an inhibitor of ornithine decarboxylase 1 (ODC1) such as difluoromethyl ornithine (DFMO). Also disclosed herein are methods of determining the presence of a type of wound and methods for treating the same, i.e. acute or non-healing wounds, which in a particular embodiment, comprises determining the ratio of putrescine versus spermidine/spermine. The present disclosure also includes methods promoting re-epithelialisation of wounds and pharmaceutical compositions for the same use.Type: ApplicationFiled: July 3, 2017Publication date: August 29, 2019Inventors: Leah VARDY, Hui Kheng LIM
-
Publication number: 20190262283Abstract: The disclosure relates to compositions and methods for treating a subject suffering from anti-NMDA receptor encephalitis. The method comprises administering to a patient in need of treatment an effective amount of tramadol before and/or during administration of therapeutic plasma exchange.Type: ApplicationFiled: February 21, 2019Publication date: August 29, 2019Inventor: Ali Seifi
-
Publication number: 20190262284Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 7, 2019Publication date: August 29, 2019Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Eran Blaugrund, Ruth Levy
-
Publication number: 20190262285Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.Type: ApplicationFiled: May 10, 2019Publication date: August 29, 2019Inventors: Gregory T. WENT, Timothy J. FULTZ, Sangita GHOSH, Natalie MCCLURE
-
Publication number: 20190262286Abstract: Disclosed herein are topical compositions comprising a quaternary ammonium salt and optionally ammonium chloride and/or stabilized chlorine dioxide. Also disclosed herein are methods of reducing the severity and/or duration of a dermal and or mucosal infection such as herpes or shingles. Also disclosed herein are methods of preventing the spread of a viral infection such as HIV. Also disclosed herein are methods of treating a viral infection such as keratoconjunctivitis.Type: ApplicationFiled: February 22, 2019Publication date: August 29, 2019Inventor: Chad ROY
-
Publication number: 20190262287Abstract: An anti-inflammatory composition is disclosed. The anti-inflammatory composition is be useful for a pharmaceutical composition or a cosmetic composition by not only having excellent stability on the skin and therefore being harmless to the human body, but also by controlling the expression of an inflammatory skin disease-related mediating factor and thereby exhibiting an excellent anti-inflammatory effect.Type: ApplicationFiled: August 25, 2017Publication date: August 29, 2019Inventors: Ji Yeon PARK, Minhee KIM, Bu-Mahn PARK, Kyung Sook YOO, Sung Woo KIM, Hye Seong SHIN
-
Publication number: 20190262288Abstract: The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.Type: ApplicationFiled: October 12, 2017Publication date: August 29, 2019Inventor: Andrew D. Levin
-
Publication number: 20190262289Abstract: A new compound composition that is free of a side effect to a liver and used for alleviating the toxicity of an acetaminophen (APAP) medicament to the liver. The compound composition comprises (a) a pharmaceutically effective amount of acetaminophen and (b) a frequently-used safe and pharmaceutically acceptable excipient that can be combined with one or more than two medicaments that can reduce the toxicity of a drug via liver enzyme CYP2E1 metabolism to the liver.Type: ApplicationFiled: May 14, 2019Publication date: August 29, 2019Applicant: NATIONAL DEFENSE EDUCATION AND RESEARCH FOUNDATIONInventors: Oliver Yoa-Pu HU, Tung-Yuan SHIH
-
Publication number: 20190262290Abstract: The invention is directed to a topical lidocaine gel composition comprising lidocaine or a salt thereof and magnesium chloride. The invention is further directed to a method of inducing local anesthesia in an eye of a patient comprising topically applying compositions of the present invention to the eye of the patient.Type: ApplicationFiled: May 15, 2019Publication date: August 29, 2019Inventor: Gerald Horn
-
Publication number: 20190262291Abstract: Disclosed herein are methods and compositions for alleviating side effects of statin administration, such as myopathic or myalgic side effects, short-term memory loss, abnormal liver function, glucose intolerance, hyperglycemia, increased risk for diabetes, or cumulative trauma disorder, comprising administration of ?-hydroxy ?-methylbutyrate (HMB) and leucic acid to an individual taking a statin. Also disclosed are methods and compositions for alleviating acute rhabdomyolysis, and methods and compositions for treating cumulative trauma disorder, comprising administration of HMB and leucic acid. The disclosure further provides uses of HMB and leucic acid in combination with a statin to alleviate side effects of statin administration, treat statin intolerance, treat cumulative trauma disorder, and treat acute rhabdomyolysis.Type: ApplicationFiled: July 19, 2017Publication date: August 29, 2019Inventor: Roland W. WINTERFIELD
-
Publication number: 20190262292Abstract: Disclosed are acidic feminine intimate cleansing compositions having a pH in the range of from 3 to 5, which further necessarily comprises at least: as a primary antimicrobial active constituent, lactic acid, which may optionally be a substituted lactic acid and/or derivative thereof; and which composition further includes an anionic constituent system which boosts the antimicrobial efficacy of the primary lactic acid constituent present; and which compositions feature low irritation, and good antimicrobial efficacy against certain species of bacteria. Treatment processes using the feminine intimate cleansing composition in treatment of the groin area of human females, and vendible products containing the feminine intimate cleansing compositions are also disclosed.Type: ApplicationFiled: October 18, 2017Publication date: August 29, 2019Applicant: RB Health (US) LLCInventors: Sarah Frances DE SZALAY, Jessica WILSON, Richard GILES
-
Publication number: 20190262293Abstract: Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the R-enantiomer are formulated to increase ketone body level in a subject. The non-racemic mixture of BHB is enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer sufficient to provide alternative benefits as discussed herein. In some aspects a composition for increasing ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 51% to 99.5% by enantiomeric equivalents of the R-beta-hydroxybutyrate and from about 49% to about 0.5% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer.Type: ApplicationFiled: May 10, 2019Publication date: August 29, 2019Inventor: GARY MILLET
-
Publication number: 20190262294Abstract: The invention relates to a composition comprising: i) one or more LDH-active anion materials comprising an LDH matrix intercalated with one or more active anions, and ii) a modifier system comprising a) one or more surfactants, in combination with b) one or more compounds having the generic formula MA, where M comprises one or more positively charged ions and A comprises one or more negatively charged counter ions.Type: ApplicationFiled: October 27, 2017Publication date: August 29, 2019Inventors: Elizabeth KING, Marcelo Leonardo BRAVO CORDERO, Ann TAYLOR-HUTCHINSON
-
Publication number: 20190262295Abstract: Resolution of a pathological condition is promoted via the application, e.g., via injection, of a potassium osmolyte such as hyperosmolar potassium gluconate, potassium aspartate, another potassium-based salt, or combinations thereof to the condition site. The application of the potassium osmolyte increases the extracellular concentration of potassium ions, reducing the membrane potential of the cells at the condition site and including immune cell quiescence. As a result, the inflammatory response in the patient to the pathological condition is reduced or eliminated. Reducing the inflammatory response is useful in treatment of myriad conditions including arthritis, auto-immune conditions, inflammatory disorders, neurodegenerative disorders, neurodevelopmental disorders, tissue breakdown, etc.Type: ApplicationFiled: February 26, 2019Publication date: August 29, 2019Applicant: Rensselaer Polytechnic InstituteInventors: Joshua Erndt-Marino, Mariah Hahn
-
Publication number: 20190262296Abstract: Exemplary embodiments provide oat fractions, and methods of producing the oat fractions, of the species Avena Sativa that has a concentration of total Avenanthramides that is from about 2 to about 25 wt. %, and up to about 30 wt. % or more, higher than the concentration before treatment with infrared energy. The higher concentration is achieved without treatment with enzymes or exposure to fungal agents to increase the concentration of total Avenanthramides. Instead, the enhanced concentration of Avenanthramides is achieved through exposure to infrared energy for a selected period of time.Type: ApplicationFiled: May 9, 2019Publication date: August 29, 2019Inventors: YiFang CHU, Jodee JOHNSON, Marianne O'SHEA
-
Publication number: 20190262297Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: October 5, 2018Publication date: August 29, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Adam D. Hughes, Erik Fenster, Melissa Fleury, Roland Gendron, Edmund J. Moran